These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12962776)

  • 1. Doxazosin GITS trough to peak ratio and 24-hour blood pressure monitoring in the management of hypertension in renal transplant patients.
    Martínez Castelao A; Ibernón M; Sarrias X; Sanz V; Moreso F; Rama I; Grinyó JM
    Transplant Proc; 2003 Aug; 35(5):1736-8. PubMed ID: 12962776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of doxazosin GITS in hypertensive renal transplant patients: comparison of 8 and 4 mg.
    Oliveras A; Hurtado S; Vázquez S; Puig JM; Lloveras J
    Transplant Proc; 2003 Aug; 35(5):1732-5. PubMed ID: 12962775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of doxazosin mesylate versus nifedipine on blood pressure variability in hypertensive patients: a randomized crossover study (SIMILAR).
    Shi J; Liang D; Pan Y; Zhang S; He M; Zhang H; Liu G; Gong Y; Wang W; Cang H; Li Y
    Blood Press Monit; 2019 Oct; 24(5):252-258. PubMed ID: 31116151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of doxazosin GITS on 24-hour blood pressure profile in patients with stage 1 to stage 2 primary hypertension.
    Lemmer B; Nold G
    Blood Press Monit; 2003 Jun; 8(3):119-25. PubMed ID: 12900589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group.
    Os I; Stokke HP
    J Cardiovasc Pharmacol; 1999 May; 33(5):791-7. PubMed ID: 10226868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambulatory blood pressure monitoring in renal transplant patients: modifiable parameters after active antihypertensive treatment.
    Oliveras A; Vázquez S; Hurtado S; Vila J; Puig JM; Lloveras J
    Transplant Proc; 2004 Jun; 36(5):1352-4. PubMed ID: 15251330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure.
    Os I
    Int J Clin Pharmacol Ther; 2006 Mar; 44(3):99-106. PubMed ID: 16550731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension.
    Os I; Stokke HP
    Blood Press; 1999; 8(3):184-91. PubMed ID: 10595697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects.
    Hermida RC; Calvo C; Ayala DE; Domínguez MJ; Covelo M; Fernández JR; Fontao MJ; López JE
    Chronobiol Int; 2004 Mar; 21(2):277-96. PubMed ID: 15332347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxazosin GITS versus standard doxazosin in mild to moderate hypertension.
    Calvo C; Gil-Extremera B; Gomez-Fernández P; Masramon X; Pueyo C; Armada B
    Int J Cardiol; 2005 May; 101(1):97-104. PubMed ID: 15860390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
    Steigerwalt SP; Brar N; Dhungel A; Butcher D; Steigerwalt S; El-Ghouroury M; Provenzano R
    Transplant Proc; 2009 Dec; 41(10):4184-7. PubMed ID: 20005365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension.
    Anegón M; Esteban J; Jiménez-García R; Sanz de Burgoa V; Martínez J; Gil de Miguel A
    Clin Ther; 2002 May; 24(5):786-97. PubMed ID: 12075946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
    Barrios V; Escobar C; Tomás JP; Calderon A; Echarri R
    Clin Ther; 2008 Jan; 30(1):98-107. PubMed ID: 18343246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: the ASOCIA Study.
    de Alvaro F; Hernández-Presa MA;
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):271-6. PubMed ID: 16495766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension.
    Takata Y; Yoshizumi T; Ito Y; Hirota Y; Fujishima M
    Angiology; 1995 Jan; 46(1):11-8. PubMed ID: 7818152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study.
    Lefebvre J; Poirier L; Archambault F; Jewell D; Reed CV; Lacourcière Y
    Can J Cardiol; 1998 May; 14(5):682-8. PubMed ID: 9627524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure.
    Mori Y; Matsubara H; Nose A; Shibasaki Y; Masaki H; Kosaki A; Okigaki M; Fujiyama S; Tanaka-Uchiyama Y; Hasegawa T; Iba O; Tateishi E; Amano K; Iwasaka T
    Hypertens Res; 2001 Jul; 24(4):359-63. PubMed ID: 11510747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.